Glycan modified short interfering RNA

US11766481B2 · kind B2 · utility

Assignees

• GanNA Bio, Inc. · US
• Children's Medical Center Corporation · US

Inventors

• Ryan Alexander FLYNN · Brookline, US
• Brian Goodman · Brookline, US
• Ciaran Lawlor · Cambridge, US
• Namita Bisaria · Somerville, US
• Richard D. Cummings · Edmond, US
• Mohui WEI · Boston, US
• Carolyn R. Bertozzi · Berkeley, US

Key dates

• Filing date: May 26, 2022
• Grant date: Sep 26, 2023
• Expiry date: May 26, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/549
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to glycan-modified nucleic acids, including short interfering RNA molecules. The glycan-modified nucleic acids include an oligosaccharide moiety that is bond to the nucleic acid and that contains a multiple antennary complex type N-glycan. The disclosure also relates to pharmaceutical compositions containing such glycan-modified nucleic acids, and methods for making and using such glycan-modified nucleic acids.